The overall objective of this contract is to advance the development of the reveal rapid AST system as an antibiotic susceptibility diagnostic test type of countermeasure to determine the treatment…

Ended Definitive Contract Awarded Last action

Contract number
75A50122C00057
Awardee
Awarding agency
Obligated
$7,625,622

Award facts

Opportunity
Contract value 20% obligated
  • $7,625,622.00 Current, with exercised options
  • $38,721,993.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Millcreek, UT 84107, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Terminate for Convenience P00007 -$4,822,170
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Supplemental Agreement for work within scope P00004 $0
Supplemental Agreement for work within scope P00003 $0
Supplemental Agreement for work within scope P00002 $1,947,792
Supplemental Agreement for work within scope P00001 $0
Original award $10,500,000

About this award

Written by GovTribe AI ·

Biofire Defense LLC received a $38.7 million firm fixed-price contract from the Office of the Assistant Secretary for Preparedness and Response (ASPR) to advance development of the REVEAL Rapid Antibiotic Susceptibility Testing (AST) System, a diagnostic countermeasure designed to rapidly identify appropriate antibiotic treatments for life-threatening infections. The contract, awarded on September 30, 2022, with a completion deadline of December 17, 2025, emerged from a Biomedical Advanced Research and Development Authority (BARDA) broad agency announcement soliciting medical countermeasures against chemical, biological, radiological, nuclear, and pandemic threats. No set-aside designation was applied to this award. Biofire Defense subcontracted with Specific Diagnostics, Inc. to support extension of the REVEAL Rapid AST System, with the subcontract awarded on September 22, 2022.

This contract reflects BARDA's continued investment in diagnostic technologies that address urgent medical preparedness needs. Biofire Defense, headquartered in Salt Lake City, Utah, brings established expertise in molecular diagnostic systems and has previously delivered FilmArray and other advanced identification platforms to federal agencies including the Department of Defense, NIH, and the Defense Health Agency. The firm's selection for this substantial development contract underscores the critical importance of rapid antibiotic susceptibility diagnostics to public health preparedness and the company's proven capability to deliver FDA-approved diagnostic solutions for infectious disease and biological threat detection.

Description

As the agency reported it.

The overall objective of this contract is to advance the development of the reveal rapid AST system as an antibiotic susceptibility diagnostic test type of countermeasure to determine the treatment for life threatening urgent infections from patient

Quick answers

Who was awarded contract 75A50122C00057?

75A50122C00057 was awarded to Biofire Defense LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2022.

How much is contract 75A50122C00057 worth?

The government has obligated $7,625,622 on 75A50122C00057. Its potential value, with all options, is $38,721,993.

Was contract 75A50122C00057 competed?

The extent of competition for 75A50122C00057 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login